Al-Warhi, Tarfah, Elimam, Diaaeldin M., Elsayed, Zainab M., Abdel-Aziz, Marwa M., Maklad, Raed M., Al-Karmalawy, Ahmed A., Afarinkia, Kamyar ORCID: https://orcid.org/0000-0003-2819-4364, Abourehab, Mohammed A. S., Abdel-Aziz, Hatem A. and Eldehna, Wagdy M. (2022) Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens. RSC Advances, 12.

Preview

PDF (PDF/A) RA-012-D2RA04385H.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (851kB) | Preview

Abstract

Microbial Multidrug Resistance (MDR) is an emerging global crisis. Derivatization of natural or synthetic
scaffolds is among the most reliable strategies to search for and obtain novel antimicrobial agents for
the treatment of MDR infections. Here, we successfully manipulated the synthetically flexible isatin
moieties to synthesize 22 thiazolyl-pyrazolines hybrids, and assessed their potential antimicrobial
activities in vitro against various MDR pathogens, using the broth microdilution calorimetric XTT
reduction method. We chose 5 strains to represent the major MDR microorganisms, viz: Methicillin
resistant S. aureus (MRSA), and Vancomycin-resistant E. faecalis (VRE) as Gram-positive bacteria;
Carbapenem-resistant K. pneumonia (CRKP), and Extended-spectrum beta-lactamase E. coli (ESBL-E), as
Gram-negative bacteria; and Fluconazole-resistant C. albicans (FRCA), as a yeast-like unicellular fungus.The cytotoxicity of compounds 9f and 10h towards mammalian lung fibroblast (MRC-5) cells demonstrated their potential satisfactory safety margin as represented by their relatively high IC50 values. The target compounds showed promising anti-MDR activities, suggesting they are potential leads for further development and in vivo studies.

Item Type:	Article
Identifier:	10.1039/D2RA04385H
Subjects:	Natural sciences
Depositing User:	Kamyar Afarinkia
Date Deposited:	01 Jul 2024 14:24
Last Modified:	04 Nov 2024 11:17
URI:	https://repository.uwl.ac.uk/id/eprint/12068

Downloads

Actions (login required)

View Item